- Home
- LVTX vs MRKR Comparison
LVTX vs MRKR Comparison
Compare LVTX & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- MRKR
- Stock Information
- Founded
- LVTX 2016
- MRKR N/A
- Country
- LVTX Netherlands
- MRKR United States
- Employees
- LVTX N/A
- MRKR N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- MRKR Health Care
- Exchange
- LVTX Nasdaq
- MRKR Nasdaq
- Market Cap
- LVTX 27.9M
- MRKR 30.7M
- IPO Year
- LVTX 2021
- MRKR N/A
- Fundamental
- Price
- LVTX $1.02
- MRKR $2.86
- Analyst Decision
- LVTX Buy
- MRKR Strong Buy
- Analyst Count
- LVTX 3
- MRKR 1
- Target Price
- LVTX $3.33
- MRKR $19.00
- AVG Volume (30 Days)
- LVTX 208.1K
- MRKR 102.2K
- Earning Date
- LVTX 12-10-2024
- MRKR 11-14-2024
- Dividend Yield
- LVTX N/A
- MRKR N/A
- EPS Growth
- LVTX N/A
- MRKR N/A
- EPS
- LVTX N/A
- MRKR N/A
- Revenue
- LVTX $7,345,000.00
- MRKR $5,395,849.00
- Revenue This Year
- LVTX N/A
- MRKR $64.48
- Revenue Next Year
- LVTX N/A
- MRKR N/A
- P/E Ratio
- LVTX N/A
- MRKR N/A
- Revenue Growth
- LVTX N/A
- MRKR 79.04
- 52 Week Low
- LVTX $0.88
- MRKR $2.44
- 52 Week High
- LVTX $6.47
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- LVTX 37.42
- MRKR 38.90
- Support Level
- LVTX $0.95
- MRKR $3.08
- Resistance Level
- LVTX $1.04
- MRKR $3.38
- Average True Range (ATR)
- LVTX 0.08
- MRKR 0.35
- MACD
- LVTX 0.03
- MRKR -0.09
- Stochastic Oscillator
- LVTX 58.16
- MRKR 5.56
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.